Pemetrexed, a new cytotoxic agent, is a potent inhibitor of thymidylate synthetase and other
folate-dependent enzymes. Firstly, pemetrexed was approved in combination with cisplatin …

Introduction: For patients with advanced NSCLC, treatment outcomes are still disappointing
and the search for new active and safe drugs is warranted. The chemotherapeutic agent …

Importance of the field: Current therapeutic options for advanced non-small-cell lung cancer
(NSCLC) yield relatively modest improvements in survival leading to an ongoing search for …

Background Subgroup analyses of randomized studies have consistently shown that
pemetrexed is exclusively effective in non-small-cell lung cancer (NSCLC) other than …

Over the past decade many large randomized trials have been conducted in patients with
locally advanced or metastatic non-small cell lung cancer (NSCLC); however, no single …

Several drugs have been approved for the treatment of patients affected by advanced non-
small cell lung cancer (NSCLC) in progression after first line chemotherapy: Docetaxel …

Pemetrexed is an antitumor agent traditionally used as monotherapy for the second-line
treatment of patients with locally advanced or metastatic non-small cell lung cancer …

Abstract On September 26, 2008, the US Food and Drug Administration approved
pemetrexed injection (Alimta® Injection; Eli Lilly and Company, Indianapolis, IN) for use in …

Until recently, the treatment of non–small cell lung cancer (NSCLC) was limited to the
cisplatin combinations, including a small number of cytotoxic drugs. More recently …

Pemetrexed (Alimta®) is a multi-targeted antifolate cytotoxic agent available for use in the
treatment of adults with advanced non-squamous non-small cell lung cancer (NSCLC). It is …